IVD in Cardiology and Neurology Market Size & Growth Forecast 2027–2036, By Segments (Product Type, End-use, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
IVD in Cardiology and Neurology Market size was valued at USD 20.74 billion in 2026 and is anticipated to grow at a 8.97% CAGR from 2027 to 2036, crossing USD 48.96 billion by 2036. The industry revenue for 2027 is assessed at USD 22.31 billion.
Get more details on this report
Request Free Sample ReportIVD in Cardiology and Neurology Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 44.82% market share in 2026, supported by advanced diagnostic infrastructure, routine biomarker testing, and strong adoption across hospitals and reference laboratories.
- Asia Pacific is expected to expand at a 10.85% CAGR, driven by broader diagnostic access, expanding hospital networks, improving laboratory capabilities, and rising use of early disease detection testing.
Segment Momentum
- Reagents & Consumables held a 63.9% share in 2026 because every diagnostic assay requires recurring purchases of test-specific reagents and single-use materials, creating continuous demand across testing facilities.
- Clinical Laboratories are expanding fastest as centralized testing, higher sample throughput, and standardized assay execution help manage rising diagnostic volumes with efficient and consistent processing.
Market Expansion Drivers
- Rising prevalence of cardiovascular and neurological disorders driven by aging global population.
- Advancements in biomarker-based diagnostics and point-of-care testing accelerating rapid clinical decision-making.
- Expansion of reimbursement frameworks and digital healthcare screening programs improving IVD accessibility in emerging markets.
Leading Market Participants
- Prominent players in the IVD in cardiology and neurology market include Abbott Laboratories (United States), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), Beckman Coulter, Inc. (United States), Becton, Dickinson and Company (United States), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (United States), Quest Diagnostics Incorporated (United States), Danaher Corporation (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 20.74 billion
- 2027 Estimated Market Size: USD 22.31 billion.
- Projected Market Size: USD 48.96 billion by 2036
- Growth Forecast: 8.97% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Reagents & Consumables (Product Type) | Hospitals (End-use) | Immunoassays (Technology)
- Emerging Opportunity Segment: Reagents & Consumables (Product Type) | Clinical Laboratories (End-use) | Molecular Diagnostics (Technology)
Market Growth Drivers and Industry Trends
Rising prevalence of cardiovascular and neurological disorders driven by aging global population
The growing burden of cardiovascular and neurological conditions among older populations is increasing diagnostic requirements, supporting the IVD in cardiology and neurology market as healthcare providers seek earlier and more accurate disease assessment. Aging is associated with a higher incidence of chronic cardiovascular conditions and neurological disorders that require repeated monitoring and diagnostic evaluation. In vitro diagnostic technologies can support the detection of relevant biomarkers and physiological abnormalities, enabling clinicians to assess disease risk, monitor progression, and guide treatment decisions across hospitals, laboratories, and other healthcare settings.
Advancements in biomarker-based diagnostics and point-of-care testing accelerating rapid clinical decision-making
Innovations in biomarker identification and point-of-care technologies are improving the speed and clinical usefulness of diagnostic testing, which will drive the IVD in cardiology and neurology market. Biomarker-based assays can provide more targeted information for assessing disease presence, severity, or progression, while point-of-care systems bring testing closer to patients and clinical decision points. Faster access to diagnostic information can support timely intervention in acute cardiovascular and neurological situations and reduce dependence on lengthy laboratory workflows for selected testing applications.
Expansion of reimbursement frameworks and digital healthcare screening programs improving IVD accessibility in emerging markets
Improving healthcare financing and the expansion of digital screening initiatives are widening access to diagnostic services, strengthening the IVD in cardiology and neurology market across emerging economies. Reimbursement mechanisms can reduce financial barriers to diagnostic testing and encourage healthcare providers to incorporate screening and monitoring into routine care pathways. Digital healthcare programs can further extend screening capabilities through remote patient engagement, electronic health information, and decentralized testing models, helping healthcare systems identify cardiovascular and neurological risks in populations with previously limited access to specialized diagnostic services.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of cardiovascular and neurological disorders driven by aging global population | 2.00% | Low | North America, Europe, Asia Pacific | High | Near Term |
| Advancements in biomarker-based diagnostics and point-of-care testing accelerating rapid clinical decision-making | 1.80% | High | North America, Europe | High | Near Term |
| Expansion of reimbursement frameworks and digital healthcare screening programs improving IVD accessibility in emerging markets | 1.40% | Moderate | Asia Pacific, Latin America, Middle East & Africa | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the IVD in cardiology and neurology market, North America held the largest share at 44.82% in 2026, supported by advanced healthcare infrastructure, strong diagnostic capabilities, and high demand for sophisticated disease detection and monitoring solutions. The region benefits from well-established clinical laboratory systems and increasing emphasis on early diagnosis and personalized patient management. Growing awareness of cardiovascular and neurological disorders is encouraging healthcare providers to adopt diagnostic technologies that support faster clinical decision-making and more effective disease monitoring. Continued investment in healthcare innovation and the integration of advanced diagnostic approaches into clinical practice further strengthens the region's position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, driven by expanding healthcare infrastructure, rising diagnostic awareness, and increasing demand for early detection of cardiovascular and neurological conditions. Improvements in access to specialized healthcare services are enabling broader use of in vitro diagnostic technologies across hospitals and diagnostic facilities. Growing healthcare expenditure, urbanization, and the modernization of laboratory capabilities are also supporting wider adoption of advanced diagnostic methods. As healthcare systems increasingly prioritize timely diagnosis and disease management, demand for reliable cardiology and neurology diagnostics is expected to expand across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Biomarker Validation FocusGermany advances IVD adoption through clinically validated assays supporting cardiovascular and neurological diagnostics. Healthcare institutions in Germany emphasize diagnostic accuracy, laboratory automation, and evidence-based testing strategies that enhance patient management across specialized care settings.
France 🇫🇷
Clinical Laboratory ExcellenceFrance emphasizes high-quality laboratory diagnostics supporting complex cardiovascular and neurological care. Healthcare organizations in France continue expanding access to validated biomarker testing while strengthening collaboration between clinical laboratories and specialist physicians.
Italy 🇮🇹
Specialized Diagnostic ServicesItaly supports IVD growth through expanding diagnostic capabilities in hospitals and specialized laboratories. Healthcare providers in Italy focus on reliable biomarker testing, laboratory modernization, and improved diagnostic pathways that enable timely clinical intervention.
Japan 🇯🇵
Early Detection SolutionsJapan promotes IVD technologies that strengthen early diagnosis of cardiovascular and neurological disorders. Diagnostic developers in Japan focus on sensitive biomarker assays, automated laboratory systems, and reliable testing solutions that support preventive healthcare initiatives.
South Korea 🇰🇷
Digital Diagnostics IntegrationSouth Korea combines advanced laboratory diagnostics with digital healthcare infrastructure for cardiology and neurology applications. Healthcare providers in South Korea prioritize automated testing, data integration, and efficient clinical workflows that improve diagnostic turnaround and patient monitoring.
United States 🇺🇸
Precision Diagnostic ExpansionThe U.S. IVD in cardiology and neurology market prioritizes advanced biomarker testing for earlier disease detection and treatment planning. Healthcare providers in the U.S. invest in high-performance diagnostic platforms and integrated laboratory workflows that improve clinical decision-making.
Segment Leadership and Growth Trends
IVD in Cardiology and Neurology Market Share (%), by Product Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Type Segment Analysis: Reagents & Consumables (Largest & Fastest-Growing Segment)
The reagents and consumables segment dominated the IVD in cardiology and neurology market in 2026, accounting for a 63.9% share, and is also expected to register the fastest growth. These products are essential to diagnostic workflows, supporting the preparation, processing, and analysis of patient samples across cardiovascular and neurological testing. Their recurring use in diagnostic procedures, combined with increasing demand for timely and accurate disease detection, strengthens their importance within the market. Continued expansion of laboratory-based testing and greater emphasis on early diagnosis are expected to sustain demand for reagents and consumables.
End-use Segment Analysis: Hospitals (Largest Segment) vs Clinical Laboratories (Fastest-Growing Segment)
Hospitals held the largest share of the IVD in cardiology and neurology market in 2026, representing 59.64% of the market. Their leading position is supported by the concentration of specialized diagnostic services, medical professionals, and patients requiring cardiovascular and neurological evaluation within hospital settings. Hospitals also facilitate the integration of diagnostic testing with broader treatment and monitoring pathways, making them important users of in vitro diagnostic solutions.
Clinical laboratories are projected to expand at the fastest pace as healthcare systems increasingly rely on specialized laboratory facilities for high-quality diagnostic testing and efficient sample processing. The ability of clinical laboratories to centralize testing, support specialized analyses, and handle diagnostic workloads makes them increasingly important to cardiology and neurology testing pathways. Growing emphasis on diagnostic accuracy, laboratory efficiency, and timely clinical decision-making is expected to encourage further adoption through this end-use channel.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product Type | Instruments, Reagents & Consumables, Software and Services | Reagents & Consumables | Reagents & Consumables |
| End-use | Hospitals, Clinical Laboratories, Others | Hospitals | Clinical Laboratories |
| Technology | Immunoassays, Molecular Diagnostics, Hematology, Others | Immunoassays | Molecular Diagnostics |
Competitive Landscape and Market Positioning
Leading companies in the IVD in cardiology and neurology market:
1. Abbott Laboratories (United States)
2. Siemens Healthineers AG (Germany)
3. F. Hoffmann-La Roche Ltd. (Switzerland)
4. Thermo Fisher Scientific Inc. (United States)
5. Beckman Coulter Inc. (United States)
6. Becton Dickinson and Company (United States)
7. Sysmex Corporation (Japan)
8. Bio-Rad Laboratories Inc. (United States)
9. Quest Diagnostics Incorporated (United States)
10. Danaher Corporation (United States)
In the IVD in cardiology and neurology market, innovation is increasingly being shaped by the convergence of advanced diagnostic methodologies and expanding clinical requirements in complex disease detection. A noticeable shift toward collaborative development frameworks is accelerating improvements in precision and test efficiency, while research-driven advancements are refining neurological and cardiovascular diagnostic accuracy. At the same time, continuous enhancement of testing platforms is reinforcing more responsive and data-driven clinical decision-making pathways across healthcare systems.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Beckman Coulter Inc. (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Sysmex Corporation (Japan) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| Danaher Corporation (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Beckman Coulter | Jul-23 | Beckman Coulter entered a partnership with Fujirebio to expand access to blood-based Alzheimer’s disease diagnostics. The collaboration combines immunoassay capabilities to strengthen development and commercialization of neurodegenerative disease testing solutions, enhancing availability of advanced in-vitro diagnostic tools for neurological conditions across clinical settings. |
| Fujirebio | Mar-23 | Fujirebio expanded its neurodegenerative disease assay portfolio with the launch of Lumipulse G NfL Blood and CSF tests. The fully automated assays enhance diagnostic capabilities for neurodegenerative conditions by enabling measurement of neurological biomarkers, supporting broader adoption of blood-based and cerebrospinal fluid testing in in-vitro diagnostics workflows. |
| Abbott | Mar-23 | Abbott received U.S. FDA clearance for the first commercially available laboratory blood test for traumatic brain injury using its Alinity i platform. The test provides objective assessment of mild TBI cases, expanding Abbott’s neurology diagnostics portfolio and strengthening its position in acute neurological care testing. |
| Siemens Healthineers AG | Mar-22 | Siemens Healthineers received FDA breakthrough device designation for its sNfL test used in multiple sclerosis diagnosis. The assay measures neurofilament light chain levels in blood and cerebrospinal fluid, strengthening its neurology diagnostics portfolio and supporting earlier detection and monitoring of nerve cell injury in clinical neurology applications. |
| BD | Mar-22 | BD partnered with Babson Diagnostics to enable at-home blood sample collection for diagnostic testing. The collaboration expands decentralized sample collection models in in-vitro diagnostics, supporting broader patient access to cardiology and neurology testing while enhancing flexibility in diagnostic workflows across non-traditional care settings. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
IVD in Cardiology and Neurology Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Area | Cardiovascular Diseases, Cerebrovascular Diseases, Neurodegenerative Diseases, Neuromuscular and Other Neurological Disorders |
| Reimbursement Category | Publicly Reimbursed Testing, Privately Reimbursed Testing, Self-Pay and Unreimbursed Testing |
| Clinical Workflow Stage | Screening and Risk Assessment, Diagnosis, Prognosis and Disease Stratification, Treatment Monitoring and Recurrence Assessment |
IVD in Cardiology and Neurology Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption Pathway Assessment |
|
| Precision Diagnostics Opportunity Mapping |
|
| Diagnostic Reimbursement Opportunity Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much is the IVD in cardiology and neurology market worth?
How is the IVD in cardiology and neurology industry projected to perform over the next decade?
How are biomarker advances and point-of-care testing transforming diagnostic adoption?
Why are reimbursement expansion and digital screening programs important for market growth?
Why do Reagents & Consumables lead the IVD in cardiology and neurology market?
Why are Clinical Laboratories the fastest-growing end-use segment in the IVD in cardiology and neurology market?
Why does North America lead the IVD in cardiology and neurology market?
What is driving growth in the Asia Pacific IVD in cardiology and neurology market?
What are the key competitors in the IVD in cardiology and neurology landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization